Abstract
Pulmonary arterial hypertension (PAH) is an incurable cardiovascular disease characterized by high blood pressure in the arteries leading from the heart to the lungs. Over two million people in the USA are diagnosed with PAH annually and the typical survival rate is only 3 years after diagnosis. Current treatments are insufficient because of limited bioavailability, toxicity, and costs associated with approved therapeutics. Aerosol delivery of drugs is an attractive approach to treat respiratory diseases because it increases localized drug concentration while reducing systemic side effects. In this study, we developed phospholipid-based aerosol microparticles via spray drying consisting of the drug tacrolimus and the excipients dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylglycerol. The phospholipid-based spray-dried aerosol microparticles were shown to be smooth and spherical in size, ranging from 1 to 3 μm in diameter. The microparticles exhibited thermal stability and were amorphous after spray drying. Water content in the microparticles was under 10%, which will allow successful aerosol dispersion and long-term storage stability. In vitro aerosol dispersion showed that the microparticles could successfully deposit in the deep lung, as they exhibited favorable aerodynamic diameters and high fine particle fractions. In vitro dose-response analysis showed that TAC is nontoxic in the low concentrations that would be delivered to the lungs. Overall, this work shows that tacrolimus-loaded phospholipid-based microparticles can be successfully created with optimal physicochemical and toxicological characteristics.
Similar content being viewed by others
REFERENCES
Archer S, Weir E, Wilkins M. Basic science of pulmonary arterial hypertension for clinicians new concepts and experimental theories. Circulation. 2010;121(18):2045–U175.
Saigal A, Ng WK, Tan RBH, Chan SY. Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. Int J Pharm. 2013;450:114–22.
Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J am Coll Cardiol. 2004;43(12s1):S13–24.
Spiekerkoetter E, Tian X, Cai J, Hopper R, Sudheendra D, Li C, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Investig. 2013;123(8):3600–13.
Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv rev. 2006;58:1009–29.
Li X, Mansour HM. Physicochemical characterization and water vapor sorption of organic solution advances spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery. AAPS PharmSciTech. 2011;12(4).
Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine. 2013;8:275–93.
Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release. 2001;70(3):329–39.
Iskandar F, Gradon L, Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanopartcile sol. J Colloid Interface Sci. 2003;265(3):296–303.
Hoe S, Ivey JW, Boraey MA, Shamsaddini-Shahrbabak A, Javaheri E, Matinkhoo S, et al. Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery. Pharm res. 2014;31:449–65.
Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary delivery. Pharmaceutical Research. 2007;24(3).
Meenach SA. High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physiochemical characterization, in vitro aerosol dispersion, and cellular studies. AAPS PharmSciTech. 2014;15(6):1574–87.
Ré M-I. Formulating drug delivery systems by spray drying. Dry Technol. 2006;24:433–46.
Hong K-H, Lee YJ, Lee E, Park SO, Han C, Beppu H, et al. Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary hypertension. Circulation. 2008;118(7):722–30.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–63.
Cho JH. Development of novel fast-dissolving tacrolimus solid-dispersion-loaded prolonged release tablet. Eur J Pharm Sci. 2014:1–7.
Gao S, Sun J, Fu D, Zhao H, Lan M, Gao F. Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-ß-cyclodextrin inclusion complex-loaded albumin. Int J Pharm. 2012;427:410–6.
Watts AB, Peters JI, Talbert RL, O'Donnell KP, Coalson JJ, Williams RO. Preclinical evaluation of tacrolimus colloidal dispersion for inhalation. Eur J Pharm Biopharm. 2011;77(2):207–15.
Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, et al. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J Control Release. 2013;167(2):189–99.
Hayes DJ, Zwischenberger JB, Mansour HM. Aerosolized tacrolimus: a case report in a lung transplant recipient. Transplant Proc. 2010;42:3876–9.
Schrepfer S, Deuse T, Reichenspurner H, Hoffmann J, Haddad M, Fink J, et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. Am J Transplant. 2007;7(7):1733–42.
Wang Z, Cuddigan JL, Gupta SK, Meenach SA. Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension. Int J Pharm. 2016;512(1):305–13.
Chen L, Nakano K, Kimura S, Matoba T, Iwata E, Miyagawa M, et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression to monocrotaline-induced pulmonary artery hypertension. Hypertension. 2011;57(2):343–50.
Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, et al. Nanoparticle-mediated delivery of nuclear factor κB into lung ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension. 2009;53(5):577–83.
Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release. 1998;51(2–3):143–52.
Mansour H, Wang DS, Chen CS, Zografi G. Comparison of bilayer and monolayer properties of phospholipid systems containing dipalmitoylphosphatidylglycerol and dipalmitoylphosphatidylinositol. Langmuir. 2001;17(21):6622–32.
Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technol. 2004;145:139–48.
Mansour HM, Sohn M, Al-Ghananeem A, DeLuca PP. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci. 2010;11(9):3298–322.
Mansour HM, Xu Z, Meenach SA, Deluca PP. Novel drug delivery systems: inhalation aerosols, pulmonary/nasal drug delivery, and nanomedicine. In: Mitra A, editor. Drug Delivery 2013.
Meenach SA, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci. 2013;49(4):699–711.
Abramoff MD, Magalhaes PJ, Ram SJ. Image processing with ImageJ. Biophoton Int. 2004;11(7):36–42.
Hickey AJ, Mansour HM. Delivery of drugs by the pulmonary route. In: Florence AT, Siepmann J, editors. Modern pharmaceutics. 2. 5th ed. New York: Taylor and Francis; 2009. p. 191–219.
Finlay WH. The mechanics of inhaled pharmaceutical aerosols: an introduction. London: Academic Press; 2001.
Mansour HM, Zografi G. The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. J Pharm Sci. 2007;96(2):377–96.
Mansour HM, Zografi G. Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface. Langmuir. 2007;23:3809–19.
Wu X, Hayes DJ, Zwischenberger JB, Kuhn RJ, Mansour HM. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug des Devel Ther. 2013;7:59–72.
Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–70.
ACKNOWLEDGEMENTS
The authors gratefully acknowledge financial support from an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103430. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Finally, the authors thank RI-INBRE for UPLC access and RIN2 for SEM, PXRD, and DSC access.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
No conflicts of interest exist.
Rights and permissions
About this article
Cite this article
Brousseau, S., Wang, Z., Gupta, S.K. et al. Development of Aerosol Phospholipid Microparticles for the Treatment of Pulmonary Hypertension. AAPS PharmSciTech 18, 3247–3257 (2017). https://doi.org/10.1208/s12249-017-0821-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-017-0821-2